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Abstract
Background: The goal of chronic hepatitis C treatment is to remove the virus to avoid progression of HCV-related
disease. Sustained virologic response (SVR) is the most widely used efficacy endpoint in clinical studies of hepatitis C,
and represents the eradication of HCV from the body. The aim of the current review was to examine the long-term
clinical, economic and quality of life benefits associated with achieving SVR.
Methods: A systematic literature review was performed using the PubMed, EMBASE and Cochrane library databases to
identify articles examining the clinical, economic and quality of life benefits associated with SVR, published in English
language from 2002–2013. For inclusion studies were required to enroll ≥100 patients and to report clinical endpoints
including hepatocellular carcinoma, overall- or liver-related mortality, or progression of disease/complications (e.g.
portal hypertension, esophageal varices). Review of economic studies on cost/cost-effectiveness of achieving SVR were
focused on studies assessing boceprevir/telaprevir plus pegIFN and ribavirin as this represents the current standard of
care in several jurisdictions worldwide. Quality of life evidence was required to use validated quality of life instruments
and provide a quantitative analysis of the impact of SVR versus no treatment or treatment failure.
Results: SVR is durable with late relapse rates over 4–5 year periods being in the range of 1–2%. Patients who
achieve SVR frequently demonstrate some regression of fibrosis/cirrhosis and have a substantially reduced risk for
hepatocellular carcinoma (relative risk [RR] 0.1–0.25), liver-related mortality (RR 0.03–0.2) and overall mortality
(RR 0.1–0.3) in comparison with no treatment or treatment failure. In the 5 years post-treatment, medical costs for
patients achieving SVR are 13-fold lower than patients not achieving SVR. Patients who achieve SVR also have health
state utility values that are 0.05 to 0.31 higher than non-responders to treatment.
Conclusions: SVR represents the fundamental goal of antiviral treatment for patients infected with chronic HCV, so as to
reduce risk of liver disease progression. Achievement of SVR has implications beyond those of clearing viral infection; it is
associated with improved long-term clinical outcomes, economic benefits and improved health-related quality of life.
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Background
On a global level over 2% of the population are esti-
mated to be infected with the hepatitis C virus (HCV),
which corresponds to a prevalent population of >180
million people with chronic infection [1]. For many pa-
tients who become chronically infected, HCV causes
slow, progressive damage to the liver and represents one
of the leading causes of cirrhosis and hepatocellular car-
cinoma (HCC) [2]. Moreover, the slow insidious nature
of disease progression means that many patients are
unaware of their status until the later stages of disease.
Six major genotypes of HCV exist in many regions
and the current standard of care for patients with HCV
genotype 1 is therapy with a direct acting antiviral (DAA)
in combination with ribavirin alone or combined with
pegIFN or a combination of two DAAs (with or without
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as this genotype occurs in all regions and is the predomin-
ant genotype in many regions.
The effectiveness of antiviral treatment, the extent to
which treatment can clear viral infection is assessed ac-
cording to the proportion of patients achieving sustained
virologic response (SVR). SVR is the fundamental goal
of treatment and is defined as undetectable (or below
the lower limit of quantification) HCV RNA at 12–24
weeks after cessation of treatment [3,4]. SVR rates with
a DAA in combination with pegIFN plus ribavirin (PR)
currently range from approx. 80–90% for treatment-naïve
patients [5-8], whilst SVR rates of up to 99% have been
reported with combinations of two DAAs [9]. Similarly,
SVR rates of up to 99% have been reported in treatment-
experienced (non-responders and relapsers) patients treated
with two-DAA combinations [10].
Although considered a surrogate endpoint (a bio-
marker indicative of viral clearance rather than a finite
endpoint such as presence/absence of disease or mortal-
ity), SVR is widely accepted as the best available indica-
tor of viral clearance and a subject with SVR is generally
considered cured [11]. Rates of late relapse are extremely
low and long-term (up to 4 years) studies of patients
treated with pegIFN have shown that SVR is durable,
with approximately 99% of patients remaining virus-free,
although the patient is still at risk of subsequent reinfec-
tion [12].
To date, the vast majority of clinical trials in HCV,
including phase III trials of boceprevir and telaprevir, have
used SVR at 24 weeks after the planned end of treatment
(SVR24) as the primary endpoint. However, research in
the field of HCV is currently advancing at a rapid pace
and SVR 12 weeks after the end of treatment is now used
as the primary endpoint in most clinical studies. The con-
cordance between SVR12 and SVR24 rates has been in-
vestigated, and a high level of concordance was observed,
suggesting that SVR12 represents a valid clinical endpoint
[13,14]. Specifically, analysis was performed by the FDA in
which data from fifteen Phase 2 and 3 trials (n = 12,000
patients) were combined to assess the concordance be-
tween SVR24 and SVR12. This analysis showed that
concordance was observed between SVR12 and SVR24
for all treatments: 98% of patients with SVR212 had
SVR24 [15].
As mentioned, SVR is the most commonly used end-
point in clinical trials in hepatitis C because the use of
incidence of HCC or liver-related mortality as an end-
point is impractical within the context of a clinical trial.
Patients with SVR following 24–48 weeks of treatment
are generally considered to be permanently cured. While
long-term follow-up is still required to fully assess the
impact of SVR on hard clinical endpoints such as the
progression to compensated or decompensated cirrhosis,
HCC and liver-related mortality, it has been shown that
patients who achieve SVR have a considerably reduced
incidence of liver-related complications in comparison
with those who fail treatment. As well as clinical impli-
cations, SVR rates can be anticipated to have an impact
on the economic burden and humanistic burden of dis-
ease. HCV-related complications, such as HCC or liver-
transplantation are associated with high direct medical
costs and high levels of healthcare resource utilization
[16], therefore any reduction in the incidence of HCV-
related complications may have a considerable long-term
economic benefit. This also extends to work productivity,
as patients with SVR have higher post-treatment employ-
ment rates than those who fail treatment [17,18]. How-
ever, in the short-term improvements in SVR rates may be
associated with increased pharmacy costs; for example, in
an analysis in the French setting Deuffic-Burban et al.
projected that the introduction of triple therapy would
lead to a 3–4 fold increase in the number of genotype 1
patients receiving treatment at a cost of EUR 497–638
million [19]. As HCV is a transmissible disease, from a
public health perspective, benefits of improved SVR rates
include a reduced prevalent population and therefore the
potential for lower transmission and incidence rates.
The objectives of the current study were to perform a
literature review to understand the link between the clin-
ical implications of achievement of SVR with the economic
and patient quality of life implications by, firstly, exploring
the clinical validity of SVR as an endpoint in terms of the
impact of SVR on the incidence of liver-related complica-
tions including mortality and HCC and secondly, to assess
the impact of attainment of SVR in terms of long-term
economic outcomes and quality of life in patients infected
with chronic HCV infection.
Methods
The search strategy for the literature review was designed
using high level Medical Subject Heading (MeSH) terms
and supplemented with free text terms and adapted for
the PubMed, EMBASE and Cochrane Library databases as
required; all initial searches were run on 08 January 2013
(subsequent searches with the same search terms were
run on 29 April 2014 to capture studies published since
the initial review was performed). For the PubMed sear-
ches, MeSH terms used included Hepatitis C [MeSH] OR
Hepacivirus [MeSH]; free-text terms were used to identify
articles focusing on sustained virologic response (wild-
cards were used to capture variations in terminology). For
the EMBASE searches, MeSH terms were mapped to
EMBASE equivalents using the “map term” functionality.
The review was limited to articles published in the last
10 years and for inclusion, studies were required to be
published in English and have a minimum enrollment of
100 patients (Table 1) (a minimum cohort size of 100 pa-
tients was chosen to focus on relatively large scale studies
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that could detect relatively small differences in outcomes
and to preclude small scale pilot studies conducted in
highly selective patient populations). The focus of the
review was on patients with HCV genotype 1, and studies
exclusively in patients with HCV genotypes 2 and 3, or in
patients with HIV coinfection, were excluded. Clinical
studies were also required to have a minimum follow up
of 1-year post-cessation of treatment, compare outcomes
in patients with SVR versus either untreated patients or
those failing to achieve SVR, and report hard clinical end-
points; studies reporting biochemical parameters only,
such as alanine amino transferase levels, were excluded.
Cost-effectiveness studies were also limited to studies
incorporating analyses of protease inhibitor-based triple
therapy regimens; studies evaluating pegIFN plus ribavirin
in comparison with pegIFN or IFN alone or no treatment
were excluded. Studies reporting on health-related quality
of life evidence were required to use validated quality of
life instruments and provide a quantitative analysis of the
impact of SVR versus no treatment or treatment failure.
The literature searches across the three databases
identified a total of 4,206 unique hits after two rounds of
screening (first round screening by title and abstract
only and second round full-text screening of short-listed
articles.) A total of 44 clinical studies (including 4 meta-
analyses), 15 quality of life studies (one additional quality
of life was identified in supplementary hand searches)
and 2 economic studies were included in the final ana-
lysis (Figure 1). The review was performed in line with
PRISMA guidance and a schematic diagram of the litera-
ture review process is shown in the Additional file 1.
Updated searches performed in April 2014 identified an




The literature review process identified a large number
of studies that examined the impact of SVR on the long-
term risk of a number of clinical outcomes including
incidence of HCC, liver transplantation, liver-related mor-
tality and overall mortality in populations with differing
levels of severity. Data were captured from a large range
of patient populations in terms of relative prevalence of
different HCV genotypes, severity of liver disease at base-
line and treatment type.
Hepatocellular carcinoma
On a global level, HCV is one of the leading causes of
HCC, and is typically associated with a poor prognosis.
A total of 34 studies [20-48] including five meta-analyses
[49-53] that examined the impact of SVR on risk of HCC
were identified (Table 2). The overwhelming consensus of
the results of the studies included was that patients who
achieve SVR have a considerably reduced risk for HCC
in comparison with untreated patients or those who fail
to achieve SVR. However, the magnitude of this effect
varied, with reported RRs for HCC in patients with SVR
versus non-responders or untreated patients ranging from
0.09–0.35.
The 2010 meta-analysis by Singal et al. showed that
patients who had SVR (following treatment with IFN
alone or IFN plus ribavirin) had a RR (95% CI) for HCC
of 0.35 (0.26–0.46) in comparison with non-responders
[49]. Similarly, the meta-analysis by Kimer et al. repor-
ted a RR (95% CI) for HCC of 0.15 (0.05–0.45); however,
the comparator group was untreated patients, rather
than non-responders to therapy [51]. Notably, the analysis
by Singal et al. included only studies in patients with
Table 1 Summary of inclusion and exclusion criteria applied in the literature review
Inclusion criteria Exclusion criteria
All studies All studies
Published 2003–2014 Conducted exclusively in HIV co-infected patients
Published in English Conducted exclusively in pediatric patients
Conducted in patients with chronic HCV Wrong publication type: letters, case studies, editorials and commentaries were excluded
Conducted exclusively in patients with genotypes 2, 3, 4, 5 or 6
Clinical studies Clinical studies
Minimum 1 year post-treatment follow-up <100 patients
Report hard clinical endpoints (e.g. overall mortality,
incidence of hepatocellular carcinoma)
Endpoints limited to biochemical parameters only (e.g. aminotransferase levels only)
Health economic studies Health economic studies
Assessing cost-effectiveness of protease inhibitors versus
pegIFN plus ribavirin, pegIFN, IFN or no treatment
Assessing pegIFN plus ribavirin versus pegIFN, IFN or no treatment
Quality of life studies Quality of life studies
Presentation of quantitative results using a validated
quality of life instrument
HCV, hepatitis C virus; HIV; human immunodeficiency virus; pegIFN, pegylated interferon; IFN, interferon.
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cirrhosis, whereas the analysis by Kimer et al. included
two studies in mixed or non-cirrhotic patients.
Studies examining the impact of SVR on risk for HCC
in Japan are of particular interest owing to the high rela-
tive prevalence of HCV genotype 1b, (which is associated
with a higher incidence of HCC than genotype 1a) and
high incidence of HCV-associated HCC in this setting.
For HCV patients with cirrhosis the annual probability
of HCC is 1–4%, although this increases to 5–8% for
patients with HCV genotype 1b [54,55]. Japan-based stud-
ies also showed that SVR was associated with reduced risk
for HCC versus non-response, although as expected the
absolute risk in both SVR and non-SVR population was
increased with advanced age and increased severity of
fibrosis. For example, Yoshida et al. determined SVR-
related gain in HCC-free survival as both a function of age
and fibrosis level (as measured by METAVIR F0–F4) [36].
For male patients with F0/F1 stage disease the gain in
HCC-free survival with SVR was 2.48 years for patients
aged 30 years, reducing to 0.15 years for patients aged
80 years. For patients with F4 stage disease SVR-induced
gain in HCC free survival was 15.98 years at age 30 years,
but only 2.38 years at age 80 years [36]. In another
Japanese study by Imazeki et al., in the overall treated
HCV population they report an annual HCC incidence of
0.5% for those with SVR versus 2.6%; whereas in patients
with cirrhosis, the corresponding figures were 1.4% and
5.9%, respectively [46]. Similar findings were reported in
other studies in the Japanese setting [22,24,29]. Only two
studies (out of thirteen) from the Japanese setting reported
no difference in the incidence of HCC for patients achiev-
ing SVR versus those without SVR [34].
Liver-related mortality
Analysis of clinical studies also showed that patients who
achieve SVR have a substantially lower risk of liver-related
mortality and overall mortality than non-responders to
treatment, irrespective of genotype, setting or disease
severity level, with a considerable proportion of studies
showing that this reduction in risk was statistically signifi-
cant (Table 3). In individual studies the RR for overall
mortality for patients with SVR versus non-response or no
treatment ranged from 0.14–0.70, whilst the correspond-
ing figures for liver-related mortality were 0.03–0.22. As
with HCC studies, the magnitude of the effect of SVR on
mortality risk varied considerably between studies, which
may be attributable in part to differences in patient char-
acteristics such as mean age and disease stage prior to
treatment. A 2010 meta-analysis reported a RR (95% CI)
for liver-related mortality of 0.23 (0.10–0.52) for SVR
patients compared with treatment failures, although if
only patients with advanced fibrosis/cirrhosis were inclu-
ded this figure decreased to 0.13 (0.06–0.29) [50]. These
findings were echoed in individual studies. For example, a
Figure 1 Diagram of literature review process. Note: the original literature searches were re-run in April 2014 to capture publications published
since the original searches. A total of twenty additional clinical articles and three additional economic studies were identified.
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Study details Key findings
Coverdale et al.
2004 [47]
Australia 455 9 yearsa Retrospective cohort study including
384 treated with IFN alone, (n = 71
untreated) including patients with cirrhosis
Overall 9-year incidence of HCC was 10%
for untreated, 11% for non-response and
2% for SVR
Van der Meer
et al. 2013 [20]
Europe and
Canada
248 8.3 yearsa Cohort of consecutive genotype 1 patients
with advanced fibrosis, 24% with SVR
HR (95% CI) for HCC for SVR versus non-SVR
was 0.20 (0.06–0.69) (p = 0.011)
Van der Meer
et al. 2012 [38]
Europe and
Canada
530 8.4 yearsa Retrospective cohort study in patients with
advanced fibrosis/cirrhosis treated with IFN,
IFN plus ribavirin or pegIFN plus ribavirin,
median follow up 8.4 years, 68% genotype 1
Rate (per 100 patient years) for HCC were
0.55 (0.14–0.96) for SVR vs. 2.63 (1.83–3.82)
without SVR (p < 0.001)
Braks et al.
2007 [43]
France 113 8.2 (3.1) years Retrospective cohort study in patients with
compensated cirrhosis treated with IFN or
pegIFN-based treatment
Proportion of patients with HCC was 2.7%
for SVR versus 31.6% for non-SVR
Cardoso et al.
2010 [42]
France 307 3.5 yearsa Retrospective analysis in patients with
bridging fibrosis or cirrhosis treated
with IFN, pegIFN or pegIFN plus ribavirin
Adjusted HR (95% CI) for non-SVR versus
SVR was 3.06 (1.12–8.39) (p = 0.029) for HCC
Bruno et al.
2007 [44]
Italy 883 96.1 months Retrospective database analysis in patients
treated with IFN monotherapy with no
cirrhosis or decompensation, 73.5%
genotype 1
Adjusted HR (95% CI) for non-SVR versus
SVR was 2.59 (1.13–5.97) (p = 0.025) for HCC
Calvaruso et al.
2013 [23]
Italy 444 69 monthsa
(range 24–130
months)
Prospective cohort study in PR-treated
patients with compensated cirrhosis,
83% genotype 1, 24% with SVR
HR (95% CI) for HCC for non SVR versus
SVR = 4.44 (1.30–15.11) (p = 0.017)
Pellicelli et al.
2013 [27]
Italy 172 5 yearsa Retrospective-prospective study in
patients with HCV genotype 1 treated
with pegIFN plus ribavirin, 34% with
cirrhosis
Multivariate OR (95% CI) for development
of HCC for no SVR versus SVR = 3.58
(0.9–14.3) (p = 0.06)
Hara et al.
2014 [24]
Japan 1,125 Not stated Retrospective cohort study in PR-treated
(SVR and non SVR) and untreated patients
HR (95% CI) for HCC for SVR versus non-SVR
and untreated = 0.12 (0.03–0.48) (p = 0.003)
Ikeda et al.
2006 [35]
Japan 2,166 15 years Retrospective cohort study in patients with
HCV patients (n = 512 untreated, n = 1,654
treated with IFN-based therapy)
Crude rate of HCC at 15 years was 13.9%
for all treated patients, 23.9% for untreated
and 7.5% for SVR
Imai et al.
2010 [28]
Japan 568 11 years Retrospective cohort study in consecutive
HCV patients treated with IFN monotherapy
HR (95% CI) for HCC for SVR versus
non-treated patients was 0.20 (0.08–0.50)
(p < 0.001) for patients <60 years and




Japan 459 8.9 (3.2) years Retrospective cohort study in patients, inc
patients with cirrhosis, treated with IFN
alone (n = 355) or untreated (n = 104),
n = 116 patients achieved SVR
In the total population, annual incidence of
HCC was 0.5% for SVR versus 2.6% for
non-responders; corresponding figures for




Japan 1,124 66 monthsa
(range 12–197
months)
Retrospective cohort study in HCV patients
treated with IFN or IFN plus ribavirin
(373 with SVR, 751 without SVR)
HCC developed in 3.5% SVR patients versus
8.1% non-SVR patients. SVR HCC patients
had a significantly more advanced stage
of fibrosis (p < 0.001)
Maruoka et al.
2012 [40]
Japan 721 9.9 (5.3) years Retrospective cohort study in patients
treated with monotherapy (n = 577, of
which n = 221 (38.3%) achieved SVR and
n = 144 untreated patients
Annual rate of HCC development was 2.71%
for untreated patients, 2.31% for non-SVR
and 0.24% for SVR (p < 0.0001)
Moriyama et al.
2005 [31]
Japan 269 >6 years Retrospective study in patients with
cirrhosis treated with IFN-based treatment
Mean annual incidence of HCC was 0.78%
for SVR versus 0.17% for non-responders with
ALT <80 IU and 4.68% for ALT >80 IU
Ogawa et al.
2013 [25]
Japan 1,013 3.6 yearsa Prospective multicenter study in patients
treated with pegIFN plus ribavirin, 70.1%
had HCV genotype 1 and 14.8% had
cirrhosis at baseline
HR (95% CI) for HCC relative to SVR = 1.50
(0.65–3.44) (p = 0.34) for relapse and
breakthrough and 3.72 (1.69–8.18) (p = 0.001)
for non-response
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large scale (N = 1,215 treatment-naïve patients), UK-based
retrospective study reported a multivariate HR (95% CI)
for liver-related death for SVR patients of 0.22 (0.09–0.58)
(p < 0.01) [56]. Similarly, an Italian study of HCV patients
(with no cirrhosis) reported that not achieving SVR
(versus SVR) increased the HR (95% CI) for liver-related
death to 6.97 (1.70–28.42) [44]. Additionally, studies in
the Japanese setting reported similar findings, with two
studies reporting RRs for liver-related mortality of
0.03–0.04 for patients achieving SVR versus untreated
patients [57,58].
The benefits of SVR in terms of reduced risk for liver-
related mortality were apparent regardless of baseline
severity. A multicenter study by van der Meer et al. [38]
with over 8 years of follow up was conducted exclusively
in patients with advanced fibrosis or cirrhosis at baseline.
Table 2 Summary of clinical studies reporting the impact of SVR on HCC (Continued)
Ogawa et al.
2012 [37]
Japan 1,015 3.8 years
(2–6 years)
Prospective multicenter study in patients
treated with pegIFN plus ribavirin
(n = 712 genotype 1, n = 303 genotype 2)
6-year cumulative incidence of HCC was
3.4% for SVR versus 21.2% for non-response




Japan 916 Not stated Retrospective study of IFN-treated patients Incidence of HCC was 3.6% in patients




Japan 236 50 monthsa N = 236 patients with IFN-based treatment,
median follow up 50 months
No significant difference in incidence of
HCC for SVR versus non-SVR
Watanabe
et al. 2011 [32]
Japan 1,865 4.25 yearsa Retrospective cohort study in patients
treated with pegIFN plus ribavirin, n = 999
(54%) with SVR
5 year cumulative incidence of HCC was
1.1% in patients with SVR and 7.1% in
non-SVR patients (p < 0.001)
Yoshida et al.
2004 [36]
Japan 2,787 >6.5 yearsa Retrospective database analysis in HCV
patients (n = 395 untreated, n = 836 SVR,
and n = 1,556 non-SVR)
HR (95% CI) for HCC for non-SVR versus
no treatment was 0.835 (0.625–1.125)
(p = ns).
Annual incidence of HCC in SVR was
0.05–0.40% for F0–F1 and 0.15–3.20%
for F4. For non-SVR annual incidence
was 0.05–1.03% for F0–F1 and 0.29–12.5%
for F4 (depending on age and gender)
Velosa et al.
2011 [39]
Portugal 130 6.4 (4.0) years Retrospective cohort study in patients
with cirrhosis treated with IFN, IFN plus
ribavirin or pegIFN plus ribavirin
HR (95% CI) for HCC for SVR versus
non-SVR was 0.09 (0.01–0.77) (p = 0.024)
Aleman et al.
2013 [26]
Sweden 351 5.3 years Prospective multicenter study in patients
with HCV-related cirrhosis treated with
pegIFN plus ribavirin, 50% genotype 1
HR (95% CI) for HCC for SVR versus
non-SVR = 0.38 (0.14–0.88) (p = 0.04)
Hung et al.
2006 [30]
Taiwan 132 37 monthsa
(12–63
months)
Retrospective cohort study in HCV patients
with cirrhosis , inc. patients with HBV or HIV
coinfection, 56% genotype 1b, treated with
pegIFN plus ribavirin
4 year cumulative incidence of HCC
was 28% in non-SVR versus 8% in SVR
group (p = 0.0178)
Shih et al.
2012 [48]
Taiwan 3,988 34.6 monthsa Retrospective analysis of patients with HCV
monoinfection, (n = 344 patients treated
with IFN-based treatment, n = 216 with SVR)
Adjusted HR (95%CI) for SVR versus
untreated was 0.23 (0.06–0.94)
(p = 0.041) for HCC
Wang et al.
2011 [33]
Taiwan 164 8 years Retrospective cohort study in patients
treated with pegIFN plus ribavirin
Incidence of HCC was 8.8% for patients
with an SVR versus 14.3% for untreated
patients (p = 0.352)
Yu et al.
2006 [45]
Taiwan 1,619 5.2 years Prospective study in patients with or
without cirrhosis (n = 562 untreated and
n = 1,057 treated with IFN or IFN
plus ribavirin)
RR (95% CI) for HCC versus untreated
was 0.245 (0.13–0.46) (p < 0.0001) for SVR








Prospective analysis from the HALT-C trial
in patients with advanced fibrosis treated
with pegIFN plus ribavirin and achieving SVR
HR (95% CI) for SVR versus non response
was 0.19 (0.04–0.80) for HCC
Wang et al.
2013 [21]
Not stated 138 8 years Patients (mean age 56 years) treated with
PR, 80% achieved SVR
8-year incidence of HCC was 13.5% for
SVR patients, 23.5% for relapsers and 20%
for non-responders (p = 0.518)
aMedian follow up.
ALT, alanine aminotransferase; CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; IFN, interferon; ns, not significant; SVR, sustained virologic
response.
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Canada 446 68 monthsa Retrospective cohort study
in liver transplant recipients
treated with IFN-based therapy
Overall survival Actuarial 5-year survival rates
were 96% for SVR and 69% for
non-response (p < 0.0001)
Tanaka et al.
2013 [60]
Canada 245 5.7 years Retrospective single center study





HR for all cause mortality for SVR
versus non-response = 0.091
(0.04–0.21) (p < 0.001). HR for all
cause mortality for relapse versus
non-response = 0.19 (0.06–0.63)
(p = 0.006)
Van der Meer
et al. 2012 [38]
Europe and
Canada
530 8.4 years Retrospective cohort study in
patients with advanced
fibrosis/cirrhosis treated with
IFN, IFN plus ribavirin or pegIFN
plus ribavirin, 68% genotype 1
All cause
mortality
HR for all cause mortality for
SVR versus non-SVR was
0.25–0.26 (p < 0.001)
Van der Meer
et al. 2012 [61]
Europe and
Canada
248 8.3 yearsa Retrospective cohort study in
patients with HCV genotype 1





Unadjusted HR (95% CI) for all
cause mortality for SVR 0.20
(0.06–0.64) (p = 0.007)
Aguilera et al.
2012 [62]
France 114 Not stated liver transplant recipients
treated with pegIFN plus
ribavirin
Overall survival For patients with F0–F1, 10 year
survival was 100% for SVR versus
76% for non-response (p = 0.024).
For patients with F3–F4, 7-year
survival was 85% for SVR versus
72% for non-response (p = ns)
Cardoso et al.
2010 [42]
France 307 3.5 yearsa Retrospective analysis in patients
with bridging fibrosis or cirrhosis




Adjusted HR (95% CI) for
non-SVR versus SVR was 3.71




France 484 4.5 yearsa Retrospective study in patients
with advanced fibrosis, SVR rate
was 30% in treated patients
All cause
mortality
5 year survival rate was 100% in
those with SVR vs. 54% for those
without SVR (p < 0.0001), HR
(95% CI) for mortality for non-SVR
versus SVR was 6.8 (2.5–20.5)
Bruno et al.
2007 [44]
Italy 883 96.1 months Retrospective database analysis
in patients treated with IFN





Adjusted HR (95% CI) for non-SVR
versus SVR was 6.97 (1.70–28.42)




Italy 444 69 monthsa
(range 24–130
months)
Prospective cohort study in
PR-treated patients with
compensated cirrhosis,




HR (95% CI) for liver related death
for no SVR versus SVR = 6.56
(2.06–20.92) (p = 0.001)
Hara et al.
2014 [24]
Japan 1,125 Not stated Retrospective cohort study




HR (95% CI) for all cause mortality
for SVR vs non-SVR and




Japan 459 8.2 (2.9) years Retrospective cohort study in
consecutive patients with CHC






Adjusted RR (95%CI) for all cause
mortality for SVR versus untreated
was 0.22 (0.07–0.71) (p = 0.0114).
Adjusted RR (95% CI) for
liver-related death was 0.03
(0.003–0.28) (p = 0.0017)
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Table 3 Summary of clinical studies reporting the impact of SVR on all-cause and liver-related mortality (Continued)
Kasahara et al.
2004 [57]
Japan 2,954 6.0 (2.2) years Retrospective cohort study in
HCV patients with stage
F0–F4 fibrosis, (n = 2,698 treated






RR (95% CI) for all cause mortality
versus untreated was 0.14
(0.06–0.35) (p < 0.001) for SVR
and 0.78 (0.43–1.39) (p = 0.394)
for non-response. RR (95% CI) for
liver-related mortality versus no
treatment was 0.04
(0.01–0.30) (p = 0.002) for SVR and
1.02 (0.54–1.90) (p = 0.962)
Maruoka et al.
2012 [40]
Japan 721 9.9 (5.3) years Retrospective cohort study in
patients treated with monotherapy
(n = 577, of which n = 221 (38.3%)






Annual liver-related mortality rate
was 2.52% for untreated patients,
1.26% for non-SVR and 0.1% for
SVR. Multivariate HR for all cause
mortality versus untreated was
0.84 (0.50–1.42) for non-SVR and
0.17 (0.08–0.40) for SVR
Uenishi et al.
2008 [64]
Japan 209 4.1 yearsa Retrospective cohort study in
patients who underwent curative
surgery for early stage HCC
(n = 139 had no antiviral
treatment, remainder treated





Tumor-free survival rate at
5 years was 54% for SVR group
versus 23% for non-SVR/untreated
group (p < 0.001)
Velosa et al.
2011 [39]
Portugal 130 6.4 (4.0) years Retrospective cohort study in
patients with cirrhosis treated




Liver-related mortality rate during
follow up was 21% for non-SVR
versus 0% for SVR
Aleman et al.
2013 [26]
Sweden 351 5.3 years Prospective multicenter study
in patients with HCV-related
cirrhosis treated with pegIFN





HR (95% CI) for liver-related
mortality for SVR versus
non-SVR = 0.18 (0.05–0.45)
(p = 0.001)
HR (95% CI) all cause mortality
for SVR versus non SVR = 0.36
(0.18–0.68) (p = 0.003)
Shih et al.
2012 [48]
Taiwan 3,988 57.7 monthsa Retrospective analysis of patients
with HCV monoinfection, (n = 344
patients treated with IFN-based
treatment, n = 216 with SVR)
Liver-related
mortality
Adjusted HR (95%CI) for SVR
versus untreated was 0.19




Taiwan 1,619 5.2 years Prospective study in patients
with or without cirrhosis (n = 562
untreated and n = 1,057 treated
with IFN or IFN plus ribavirin)
Overall
morality
RR (95% CI) for overall mortality
versus untreated control was 0.37
(0.14–0.99) (p = 0.047) for SVR





1,215 5.3 years Retrospective cohort study in
previously naïve patients, 36%
genotype 1, treated with IFN-based




Adjusted HR (95% CI) for SVR
versus non-SVR was 0.22
(0.09–0.58) for liver-related





22,942 3.8 yearsa Retrospective database analysis in
n = 12,166 genotype 1, n = 2,904
genotype 2, and 1,794 genotype 3




Adjusted HR (95% CI) for all cause
mortality for SVR versus non SVR
in HCV genotype 1 was 0.70





358 10 years Retrospective database analysis in
patients with HCV treated with IFN
monotherapy or pegIFN plus
ribavirin, 69% genotype 1 and 7.3%
with cirrhosis at baseline
All cause
mortality
HR (95% CI) for death or liver
transplant vs. never treated
patients = 0.23 (0.07–0.75) for






536 7.5 yearsa Retrospective chart review of
treated patients, 70% genotype 1,






HR (95% CI) for all cause mortality
for SVR vs. non-SVR = 0.47
(0.26–0.85) (p < 0.012)
HR (95% CI) for liver-related
death or transplant for SVR vs.
non-SVR = 0.23 (0.08–0.66)
(p = 0.007)
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Van der Meer showed that SVR led to a 3-fold reduction
in the overall mortality rate (1.01 [0.46–1.56] per 100 pa-
tient years for SVR versus 2.93 [2.36–3.51] per 100 patient
years for those without SVR; p < 0.001) and a 30-fold re-
duction in liver-related mortality or transplant (0.23
[0.01–0.50] per 100 patient years for SVR versus 3.20
[2.58–3.82] per 100 patient years for those without SVR;
p < 0.001) [38].
Overall mortality
Achievement of SVR has also been shown to reduce the
risk of overall mortality (Table 3). For example, in a US-
based study, SVR was associated with a HR (95% CI)
versus non SVR for all-cause mortality (for genotype 1
only) was 0.70 (0.59–0.83) (p < 0.0001) [65]. Other stud-
ies report a much lower figure, with Morgan et al.
reporting a HR (95% CI) for all-cause mortality or liver
transplant of 0.17 (0.06–0.46) [41].
Other complications
Four studies identified in the review (conducted in
Japan, Spain and the United States), showed that pa-
tients with SVR had a reduced risk for new onset dia-
betes in comparison with those not achieving SVR; in
patients who achieved SVR the risk of developing dia-
betes was approximately 2-fold lower than for patients
who failed treatment (Table 4). In all four studies investi-
gating this associated the reduced risk for type 2 dia-
betes with SVR was statistically significant [69-72].
Economic implications
The incidence of late stage complications associated
with HCV (e.g. HCC, decompensated cirrhosis and liver
transplant) is a major contributor to the economic bur-
den associated with HCV. In the US alone, direct annual
costs associated with HCV exceed USD 1 billion [82],
with annual per patient costs exceeding USD 50,000 for
HCC and USD 110,000 for a single liver transplant [83].
Similarly, in Europe, a 5-country study by Vietri et al.
showed that HCV patients have a high level of medical
resource utilization leading to high direct costs as well
as a high degree of absenteeism and presenteeism
leading to high indirect costs. Indeed, Vietri et al. report
direct annual costs of EUR 1,147 and indirect costs of
EUR 7,533 per patient [84]. New antiviral treatment reg-
imens that increase the SVR rate have the potential to
influence future complication rates and therefore the
overall economic burden; however, as triple therapy regi-
mens are also associated with increased pharmacy costs
in comparison with pegIFN plus ribavirin alone, cost-
effectiveness analyses are required in order to quantify
the estimated long-term clinical and economic benefits.
The initial literature review and update captured a total
of five studies that specifically assessed the economic
benefits of treatment in terms of cost per SVR achieved
or cost of SVR versus failure (Table 5) [85-89].
One 2013 US-based study Manos et al. examined fol-
low up costs for patients achieving SVR versus non-
responders over a 5-year period [89]. They report that
patients with SVR (all genotypes) have mean annual
costs (2007 USD) of USD 6,301 versus USD 10,149 for
non-SVR patients, with the difference attributed to
higher hospital costs (USD 5,167 versus USD 2,641) and
outpatient costs (USD 4,983 versus USD 3,661). A simi-
lar UK-based analysis reported that costs in the 5 years
post-treatment were 13-fold higher for patients who
failed treatment versus those who achieved SVR, which
increased to 56-fold for patients who initially failed
treatment and were then retreated [85].
Three cost-effectiveness analyses presented results in
terms of cost or incremental cost per SVR achieved
[86-88]. In an Italian-based analysis Camma et al. re-
ported an incremental cost per SVR achieved (versus
pegIFN plus ribavirin) of EUR 60,500 per SVR for boce-
previr IL28B guided therapy and EUR 74,600 per SVR
for telaprevir IL28B guided therapy (2011 EUR) for
treatment-naïve patients with HCV genotype 1. How-
ever, a key limitation of this analysis is that US pharmacy
costs were used as Italian costs were not available at the
time of the analysis, which may have led to under- or
over-estimation of the true cost-effectiveness [87]. An-
other analysis from the Greek setting showed that for
the overall HCV genotype 1 population (including treat-
ment naïve patients and prior non-responders and







Prospective analysis from the
HALT-C trial in patients with advanced
fibrosis treated with pegIFN plus






HR (95% CI) for SVR versus non
response was 0.17 (0.06–0.46) for
all cause mortality or transplant






242 5 years Retrospective single center study in
patients treated with pegIFN plus




HR for mortality for SVR versus
non-response = 0.11 (0.03–0.47)
aMedian follow up.
ALT, alanine aminotransferase; CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; IFN, interferon; ns, not significant; SVR, sustained
virologic response.
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et al. 2004 [47]
Australia 455 9 yearsa Retrospective cohort study
including 384 treated with
IFN alone, (n = 71 untreated)
including patients with cirrhosis
Liver-related
complications
Overall 9-year incidence liver-related
complication rate was 25% for
untreated, 25% for non-response
and 2% for SVR
Abergel et al.
2004 [73]
France 163 Not stated Retrospective cohort study in
patients with severe fibrosis
treated with IFN alone (n = 64)
or IFN plus ribavirin (n = 99)
Progression
of fibrosis
Fibrosis progression rate decreased
in both responders and non-responders
to treatment. 33% SVR regressed from
cirrhosis to severe fibrosis; corresponding




France 113 8.2 (3.1)
years
Retrospective cohort study in
patients with compensated
cirrhosis treated with IFN, IFN




Proportion of patients with ascites was
5.4% for SVR vs. 10.5% for non-SVR,
rates of digestive hemorrhage were
2.7% vs. 5.3%, respectively
Poynard et al.
2013 [74]
France 933 6.3 years Prospective cohort study in





HR (95% CI) for regression of fibrosis
at 10 years for SVR versus non-response =
4.94 (2.59–9.44) (p < 0.001)
HR (95% CI) for progression to
cirrhosis = 0.185 (0.106–0.264) for





Open label study in with liver
transplant recipients treated
with IFN plus ribavirin or
pegIFN plus ribavirin,
75% genotype 1
Fibrosis stage For SVR mean (SD) necroinflammatory
grade decreased from 1.9 (0.6) to 1.0
(0.6) post-therapy and improved in
71.5% and remained stable in 26%
SVR patients; corresponding figures in




Germany 718 35 years Prospective, community-based
multicenter study in women
with HCV genotype 1, SVR
rate of 46% in treated patients
Cirrhosis Incidence of cirrhosis at 35 years
post-infection = 6.0% for SVR vs.
15.3% for non-SVR
Annicchiarico
et al. 2012 [77]
Italy 135 44.4
monthsa
Prospective study in 135
HCV patients with cirrhosis
Portal
hypertension
Development of portal hypertension
was 10% for SVR versus 40% for non-SVR
(p < 0.0005) progression of portal
hypertension was 25% for SVR vs.
48% for non-SVR (p < 0.01)
Bruno et al.
2010 [78]
Italy 218 11.4 yearsa Retrospective cohort study in
patients with compensated
cirrhosis (n = 149 patients treated
with IFN or IFN plus ribavirin),
but no esophageal varices
Esophageal
varices
Esophageal varices developed in
32% untreated patients, 39% non-SVR
patients and 0% SVR patients
D’ambrosio et al.
2011 [79]
Italy 127 77 months Prospective cohort study in
initially treatment-naïve
patients with compensated








in 5% SVR patients versus 15% non-SVR
patients. 8-year cumulative probability
of esophageal varices was 6% for
SVR vs. 30% for non-SVR (p = 0.03)
Arase et al.
2009 [69]
Japan 2,842 6.4 yearsa Retrospective cohort study
in patients treated with IFN or
pegIFN plus ribavirin, 6% patients
had cirrhosis at baseline
Onset of type
2 diabetes
Adjusted HR (95% CI) for the
development of diabetes for non-SVR
vs. SVR was 2.73 (1.77–4.20) (p < 0.001)
Imazeki et al.
2005 [46]
Japan 459 8.9 (3.2)
years
Retrospective cohort study in
patients, inc patients with
cirrhosis, treated with IFN alone
(n = 355) or untreated (n = 104),
n = 116 patients achieved SVR
Hepatic failure In the total population, annual incidence
of hepatic failure was 0% for SVR and
0.5% for non-responders; corresponding
figures for patients with cirrhosis were
0% and 1.0%, respectively
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relapsers), that telaprevir-based triple therapy was dom-
inant to pegIFN plus ribavirin in terms of cost per SVR
gained (telaprevir was associated with a cost-saving of
EUR 10,403 per SVR gained) [88].
Quality of life
The literature review process identified a total of 15
studies that examined HRQoL in patients with SVR
[17,90-103], and a further study was identified via
searches of the bibliographic sections of included studies
[18]. The most commonly used instrument in HRQoL
studies was the SF-36, and studies that used this almost
universally showed that patients with SVR had better
scores than non-responder/relapser/untreated popula-
tions, both in terms of sub-domains and physical and
mental component summary scores, with a large propor-
tion of between group differences achieving statistical
significance. On an individual domain level, in studies
that used the SF-36, the largest differences between pa-
tients with SVR and those without were reported for
general health followed by role physical [18,103].
A total of seven studies (including two cost-
effectiveness analyses of triple therapy), reported utility
values for SVR using a number of different methods in-
cluding standard gamble, time trade off (TTO) and the
Health Utilities Index Mark 3 (HUI3) (Table 6). In one
Table 4 Summary of clinical studies reporting the impact of SVR on liver-related complications (Continued)
Uenishi et al.
2008 [64]
Japan 209 4.1 yearsa Retrospective cohort study
in patients who underwent
curative surgery for early stage
HCC (n = 139 had no antiviral
treatment, remainder treated





Tumor-free survival rate at 5 years
was 54% for SVR group vs. 23% for








86% patients treated, 15% with
cirrhosis at baseline, SVR
rate of 75%
Cirrhosis Cumulative 5 year rate of cirrhosis
was 27.6% for patients without SVR
vs. 0% for patients with SVR (p < 0.01)
Canete et al.
2013 [81]
Spain 105 9.3 years Retrospective study of paired
biopsy data in HCV patients
with mild-moderate fibrosis
treated with IFN plus ribavirin
Progression
of fibrosis
Progression of fibrosis was reported
in 5.3% patients with SVR and 50%
patients with non-response (p < 0.0001).
Fibrosis improved in 30.5% patients




Spain 234 5.7 years Retrospective cohort study in
patients with HCV (without
severe fibrosis) treated with




HR (95% CI) for onset of diabetes for




Sweden 351 5.3 years Prospective multicenter study
in patients with HCV-related
cirrhosis treated with pegIFN





HR (95% CI) for hepatic
decompensation for SVR vs. non





1,215 5.3 years Retrospective cohort study in
previously naïve patients, 36%
genotype 1, treated with
IFN-based therapy, 14% patients





Adjusted HRs (95% CI) for SVR
versus non-SVR were 0.22 (0.15–0.34)






358 10 years Retrospective database analysis
in patients with HCV treated
with IFN monotherapy or pegIFN
plus ribavirin, 69% genotype 1
and 7.3% with cirrhosis at
baseline
Cirrhosis HR (95% CI) for development of
cirrhosis vs. never treated = 0.68






20,486 5 years Retrospective database analysis
of US veterans with no history




HR (95% CI) for onset of type 2
diabetes for SVR versus non-response





8,687 >6 years Retrospective database analysis




Rate of new onset of diabetes was
10.2% for SVR group vs. 15% for
non-SVR group
aMedian follow up.
ALT, alanine aminotransferase; CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; IFN, interferon; ns = not significant; SVR, sustained
virologic response.
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Table 5 Summary of literature relating to the health economic implications of SVR




genotype 1 with F2 fibrosis
in Brazil
Boceprevir plus PR and
telaprevir plus PR
In the public health system cost per SVR
was BRL 50,751 for telaprevir plus PR and
BRL 63,481 for boceprevir plus PR. In the
private health system cost per SVR was
BRL 88,508 for telaprevir plus PR and BRL
82,518 for boceprevir plus PR
Backx et al.
2014 (UK) [85]
Treated genotype 1 patients Patients treated with PR for
a minimum of 2 months
For non-cirrhotic patients 5-year post-treatment
costs were 13-fold higher for non SVR patients
vs. SVR (GBP 2,530 versus GBP 190), and 56-fold




Treatment-naïve HCV genotype 1,
aged 50 years with F2 fibrosis
Boceprevir- or telaprevir based
triple therapy (including RGT)
versus pegIFN plus ribavirin alone,
time horizon of 20 years
ICER per SVR versus pegIFN plus ribavirin was









In total population, mean cost per SVR was
EUR 46,635 for telaprevir and EUR 56,146 for
boceprevir. For treatment-naïve population
cost per SVR was EUR 38,868 and EUR 42,983,
respectively. For treatment-experienced patients
cost per SVR was EUR 48,966 and EUR 59,902
respectively. Telaprevir was dominant to boceprevir
Manos et al. 2013
(United States) [89]
Chronic HCV patients treated
from 2002–2007, excluding
pre- and post-liver transplant
antiviral treatment
PegIFN plus ribavirin In the 5 years following treatment mean
yearly total (hospital and outpatient) costs in
genotype 1 patients were USD 2,504 higher for
non-responders than for patients with SVR (p = 0.042)
HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; RGT, response-guided therapy; SVR, sustained virologic response.
Table 6 Health state utilities for HCV patients achieving SVR
Method Study Value Difference
SVR Non-response/relapse
EQ5D Thein et al. 2005 [93] 0.83 ― ―
Chong et al. 2003 [95] 0.83 0.76c 0.07
Van Rooijen et al. 2011 [99] 0.84 0.70 0.14
SF-36 Thein et al. 2005 [93] 0.74–0.90 0.70–0.86b 0.04–0.05
SF-6D Hsu et al. 2012 [103] 0.71 0.66c 0.05
John-Baptiste et al. 2009 [18] 0.71 0.65 0.06
HUI3 Thein et al. 2005 [93] 0.77 ― ―
John-Baptiste et al. 2009 [18] 0.70 0.58 0.12
Hsu et al. 2012 [103] 0.70 0.57c 0.13
HUI Chong et al. 2003 [95] 0.77 0.73c 0.04
TTO John-Baptiste et al. 2009 [18] 0.89 0.84 0.05
Hsu et al. 2012 [103] 0.88 0.80c 0.08
SG Thein et al. 2005 [93] 0.86 ― ―
Chong et al. 2003 [95] 0.86 0.79c 0.08
VAS Thein et al. 2005 [93] 0.74 ― ―
Chong et al. 2003 [95] 0.74 0.70c 0.04
Not stated Liu et al. 2012 [104] 0.933–1.00a ― ―
Chhatwal et al. 2013 [105] 1.00 ― ―
HUI3, Health Utilities Index Mark 3; SF-36, Medical Outcomes Study 36-item Short-Form Health Survey; SG, standard gamble; TTO, time trade off; VAS, visual analog scale.
aAge-specific quality of life weight.
bUntreated.
cPatients with mild/moderate HCV or chronic infection.
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cost-effectiveness analysis by Liu et al. the mean utility
value associated with SVR was dependent upon whether
the subject had mild fibrosis or cirrhosis [104]. Previous
studies have shown that HRQoL is influenced by disease
severity, but the study by Liu et al. is one of the few
studies to suggest the quality of life benefit of SVR is
influenced by baseline disease severity. Utility values as-
sociated with the SVR state were strongly influenced by
the method of assessment used and were typically high-
est using the TTO (ranging from 0.88–0.89) and stand-
ard gamble methods (0.86) (Table 6) and lowest using
the SF-6D (0.71) and visual analog scale methods (0.74).
Additionally, assessment of utility values using the EQ-
5D valuation index led to values of 0.83–0.84 for SVR in
comparison with 0.70–0.76 for non-response/relapse
(Table 6) [95,99].
Most quality of life studies included in the review
assessed HRQoL within the first year following treat-
ment; however two studies assessed the impact of SVR
at >3 years after completion of antiviral therapy. Both
Mauss et al. [17] and John-Baptiste et al. [18] reported
that the HRQoL benefits of SVR persist over >3 years,
with both studies showing that patients with SVR had
significantly better scores in all eight domains of the SF-
36 in comparison with those who had failed treatment.
Both Mauss et al. [17] and John-Baptiste et al. [18] also
showed that SVR was associated with long-term benefits
in terms of work productivity. Mauss et al. reported that
a significantly higher proportion of patients who achieved
SVR were employed (56%) in comparison with non-SVR
patients (41%; p < 0.0001) [17]. Similarly, John-Baptiste et
al. reported employment figures of 67% for patients with
SVR versus 51% for those who failed treatment (p = 0.02).
This analysis also showed that long-term work and leisure
capacity were significantly compromised in treatment
failures in comparison with the SVR group. Treatment
failures had a mean (SD) reduction in work capacity of 5.8
(18)%, versus 1.1 (6)% for SVR; the corresponding figures
for reduction in leisure capacity were 10.7 (24)% and 3.3
(13%), respectively [18].
Discussion
The overarching aim of the present review was to consoli-
date published findings relating to the clinical, economic
and quality of life benefits associated with achieving SVR
and draw together these data to assess how clinical and
quality of life benefits translate into economic benefits on
both a per-patient and system-wide level. Previous re-
search has largely focused on individual clinical, economic
or quality of life aspects of SVR and has not examined
how these benefits overlap and interact within a larger
framework. For example, on an individual patient level,
attainment of SVR is associated with lower risk of progres-
sion, HCC and liver-related mortality, less time spent in
hospitals and improved symptoms and quality of life.
However, when scaled up to a system wide level, SVR
translates into substantial direct cost-savings for the payer
due to costly complications avoided, as well as lower indir-
ect costs due to lost productivity through absenteeism and
presenteeism.
SVR is widely regarded as a cure and has been shown
to be durable with rates of late relapse being in the re-
gion of 1–2%. In addition to halting progression of liver
damage, SVR-induced regression of fibrosis and even cir-
rhosis has been reported. For example in a meta-analysis
of 8 European studies, Veldt et al. reported regression of
fibrosis in approximately one third of patients achieving
SVR [106]. Additionally, risk factors such as heavy alcohol
use or co-infection with hepatitis B may lead to pro-
gression of liver disease even in the presence of SVR.
The clinical implications of potential low level viral per-
sistence are not well characterized and it remains largely
unknown whether it influences post-SVR progression of
liver disease.
There is extensive evidence relating to the clinical ben-
efits of SVR. A reduced risk for progression to cirrhosis,
HCC, liver transplantation and liver-related mortality is
evident regardless of setting, age, HCV subtype or level
of fibrosis (Tables 2, 3, 4 and 7). However, the magnitude
of the impact of SVR in terms of its impact on mortality
rates varied notably between studies identified in this re-
view, with some studies suggesting that following SVR
the risk for liver-related mortality is comparable to that
of the general population, whilst others suggest that mor-
tality risk, although lower than for treatment failures, re-
mains elevated in comparison with the general population.
A contributing factor in this disparity may be heterogeneity
in populations studied. Some studies excluded patients
with advanced fibrosis or cirrhosis, whilst others were
conducted exclusively in cirrhotic patients; there were also
differences between patient populations in terms of age,
previous treatment history, and the relative prevalence of
different HCV genotypes.
The absolute risk and the magnitude of benefit does
appear to be highly dependent on age and pre-treatment
level of fibrosis. One study by Yoshida et al. [36] in the
Japanese setting assessed the gain in HCC-free survival
(defined as the difference in expected HCC-free survival
with SVR versus without) according to age and fibrosis
level. They report that the gain in HCC-free survival was
greater when the subject was younger and had advanced
fibrosis at baseline. For example for patients with stage
F2 fibrosis the RR (95% CI) for HCC were 1.76 (0.47–
6.67) for SVR versus 2.86 (1.59–5.13) for non-SVR,
whereas for patients with F4 fibrosis the RRs (95% CI)
increase to 4.78 (1.13–20.18) and 12.23 (6.81–21.95), re-
spectively. A large proportion of the HCC studies identi-
fied in the current review (n = 11/24) were conducted in
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the Japanese setting, which has among the highest
incidence of HCV-related HCC in the world, with an
estimated 30,000 deaths per year attributable to HCC
[36] and a mean annual treatment cost of USD 42,360
in Japan (2010 USD) [16]. As such, even a modest reduc-
tion in HCC, such as 100 cases avoided per year, would
lead to savings of over USD 4 million for the payer.
The underlying reason for the high HCC rate in Japan
is thought to be partly due to the high relative preva-
lence of genotype 1b (which is associated with a higher
risk for HCC development in comparison with other
genotypes [108]) relative to the US and Europe, and also
to the fact that the spread of HCV is thought to have
begun earlier in Japan than in Europe and North America,
[109] therefore leading to an older prevalent population,
with more advanced disease and therefore higher risk for
developing HCC.
The clinical benefits of SVR are not limited to HCC.
Patients with SVR have reduced risk of progression,
liver-related mortality, liver transplantation and overall
mortality in comparison with those not achieving SVR.
Liver transplantation has a mean (global) cost of USD
146,960 in the year of transplant [16], so again even small
reductions in the number of liver transplants required
translate into substantial savings for the payer. The risk of
overall mortality is reduced by approximately 5-fold, and
liver related mortality approximately 10-fold, versus non-
SVR, although this is influenced by age and level of fibro-
sis prior to treatment.
Patients with HCV have been shown to be at elevated
risk for co-morbid conditions including type 2 diabetes
[110]. Three studies showed that patients with SVR had
a lower incidence of new onset diabetes versus non-
responders. The mechanism for this is not clear, although
hypotheses include elevated insulin resistance caused by
pro-inflammatory cytokines [71]. It is has also proposed
that insulin resistance may influence the likelihood of
achieving SVR, rather than SVR influencing diabetogenic
processes [111]. HCV is associated with a number of other
extra-hepatic complications, although there are a lack of
data on the impact of SVR on these.
The clinical benefits associated with SVR due to com-
plications avoided translate into economic benefits from
a third party perspective. The magnitude of economic
benefit is difficult to quantify, due to uncertainty of preva-
lence estimates and continued advances in therapy leading
to ongoing improvements in SVR rates but owing to the
high cost, even a small reduction in the incidence of
HCC would have considerable economic implications.
In addition to direct costs, the attainment of SVR also
has implications on indirect costs such as lost product-
ivity, with evidence to suggest that employment rates
Table 7 Meta-analyses of long-term clinical outcomes in patients with SVR
Study Details Outcomes assessed Key findings
Almasio et al.
2003 [107]
Systematic review and pooled analysis
(N = 1,031 patients for cirrhosis analysis,
N = 3,914 patients for HCC analysis)
HCC, progression to cirrhosis Risk reduction for progression to cirrhosis for
SVR versus no SVR = −0.22 (−0.36 to −0.08). Risk
reduction for HCC = −0.097 (−0.13 to −0.07)
Kimer et al.
2012 [51]
Systematic review and meta-analysis of 8
RCTs and 5 prospective studies (N = 3,208 patients);
random effects model used. Patients treated
with IFN, pegIFN or PegIFN plus ribavirin
HCC RR (95% for HCC for SVR versus no
intervention = 0.15 (0.05–0.45)
Morgan et al.
2013 [53]
Systematic review and meta-analysis of
30 studies (N = 31,528 patients)
HCC For patients at all stages of disease
HR (95% CI) for HCC for SVR versus
non-response = 0.24 (0.18–0.31)
(p < 0.001)(18 studies included in meta-analysis) investigating
impact of treatment on risk for HCC
For patients with advanced liver disease
HR (95% CI) for HCC for SVR versus
non-response = 0.23 (0.16–0.35) (p < 0.001)
Singal et al.
2010 [49]
Systematic review and meta-analysis of
20 studies (N = 4,700 patients) in treatment-naïve
patients treated with IFN or IFN plus ribavirin;
random effects model used
HCC RR (95% CI) for HCC for SVR versus
non-responders = 0.35 (0.26–0.46)
Singal et al.
2010 [50]
Systematic review and meta-analysis of 26
studies (N = 13,191 patients)
HCC, hepatic decompensation,
liver-related mortality
RR (95% CI) for SVR versus treatment failure
were: HCC 0.21 (0.16–0.27) (p = ns)
for all patients and 0.27 (0.19–0.39)
(p = ns) for patients with cirrhosis.
Liver-related mortality was 0.23 (0.10–0.52)
(p = ns) for all patients and 0.13 (0.06–0.29)
(p = ns) for patients with cirrhosis. RR (95% CI)
Hepatic decompensation 0.16 (0.04–0.59)
(p = ns) for all patients and 0.08 (0.03–0.21)
(p = 0.02) for patients with cirrhosis
CI, confidence interval; HCC, hepatocellular carcinoma; RCT, randomized controlled trial; RR, relative risk.
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are higher amongst patients with SVR versus those
without [17,18].
The clinical benefits associated with the achievement
of SVR translate into clinically meaningful benefits for
patients by improving symptoms, functioning and health
related quality of life, compared with those not able to
achieve SVR. The findings of quality of life studies con-
sistently showed that patients with SVR had higher util-
ity values and SF-36 and EQ-5D scores in comparison
with those who did not respond to treatment. However,
in the literature review it was noted that there is a pau-
city of quality of life studies with long-term follow-up
(≥5 years). Although SVR leads to improved quality of
life in the short-term, data relating to whether or not
this improvement persists in the long term are lacking.
Although the scope of the present review was such
that the endpoints of fatigue and depression were not
assessed directly, SVR is also associated with other benefits
in terms of patient reported outcomes including fatigue
and depression, which are common side effects associated
with antiviral treatment. The Fatigue Severity Scale (FSS)
is a commonly used instrument to assess fatigue in HCV
studies. The FSS has good reliability, validity and respon-
siveness and a total score ≥4 is indicative of severe fatigue.
In addition to improved SVR, protease inhibitors are asso-
ciated with benefits in terms of reduced fatigue. Published
data relating to the magnitude of change in FSS score
required to constitute a minimally important difference
are lacking. However, analysis of phase III simeprevir trial
data indicate that a clinically meaningful change (improve-
ment or worsening) may be as small as 0.33–0.34 and that
patients with SVR have significant improvements in FSS
score versus non-responders (Janssen, data on file).
The current study has several limitations that should
be acknowledged with regard to interpretation of the
findings. In particular, the review included studies that
compare SVR groups with both untreated groups and non-
responder groups. Several studies in Japan have shown that
risk of HCC and overall mortality are reduced, although
not significantly in patients who receive treatment but fail
to achieve SVR in comparison with untreated patients,
although the mechanism behind this is poorly understood
[57,112]. Moreover, in a considerable proportion of the
studies reported here no distinction is made by the authors
in the non-SVR groups in terms of null-response, partial
response or relapse following treatment. The potential
benefits of SVR in relapsers is an area that warrants
further investigation as two studies included here sug-
gested that patients who relapse have lower risks for
overall mortality and HCC in comparison with true
non-responders [37]. Similarly, whether benefits of SVR
are different across different sub-populations, such as
patients with hepatitis B or HIV coinfection, or is influ-
enced by genotype, is an issue for future analysis. A
further limitation of the current review is that no formal
quality assessment of included studies was performed.
While this systematic literature review attempted to be
as holistic as possible in capturing the impact of achiev-
ing SVR in patients chronically infected with hepatitis C,
it was not possible to capture all possible consequences.
For example, the benefits associated with reduced infec-
tion risk were not considered, and therefore represent a
limitation of the review. Additionally, during the litera-
ture search it was noted that an aspect of HCV that is
often overlooked in the literature is the stigma associated
with HCV and the impact of this on patients’ quality of
life, disclosure practices and treatment-seeking behavior.
Stigma may be subtle and is inherently difficult to quan-
tify. One of the key factors in stigma arises due to fear of
transmission, which although limited to blood-borne
routes, does not prevent stigma. Patients with SVR are no
longer at risk of transmitting HCV to others, therefore the
stigma associated with HCV should be removed. Another
aspect to consider is the public health benefit associated
with a lower population prevalence; a reduced population
prevalence means that there are fewer people from whom
HCV can be transmitted to others.
Conclusions
In conclusion, review of the literature has shown that
achievement of SVR in patients with chronic HCV infec-
tion is associated with significant clinical, economic and
quality of life benefits. Patients who achieve SVR, including
those with advanced disease, have a substantially reduced
risk of progression to cirrhosis, development of HCC and
both liver-related and all cause mortality. This reduced risk
of late stage complications also leads to economic benefits.
Post-treatment, patients with SVR also have lower health-
care resource utilization versus non-responders, which
also translates into substantial economic benefits from a
healthcare payer perspective. Finally, the attainment of
SVR is also associated with improved quality of life.
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